Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 8/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.97 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.97 |
| ▸ | TTR | P02766 | 3/20 | 0.97 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.97 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.97 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.97 |
| ▸ | ALB | P02768 | 1/20 | 0.97 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.97 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.97 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.97 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.97 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.97 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofenac SCHEMBL2799 | 0.98 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL29354260 | 0.98 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL996716 | 0.98 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL2216520 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL24010 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL1178502 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL4614418 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL22370200 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL22129258 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL40785 | 0.97 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024047-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024049-A1 | PROTEIN CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| EP-0987023-A1 | Transition metal complexes of non steroidal anti-inflammatory drugs | PANACEA BIOTEC LIMITED (IN) | 2000-03-22 | — | — | EP | disclosed |
| CN-1240648-A | Transition metal complexes of non steroidal anti-inflammatory drugs | PANACEA BIOTEC LTD (IN) | 2000-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | PTGS2 114/4885PTGS1 31/4885CXCL8 958/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | PTGS2 114/4885PTGS1 31/4885CXCL8 958/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | PTGS2 2908/4885PTGS1 2524/4885CXCL8 3230/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | PTGS2 535/4885PTGS1 470/4885CXCL8 1169/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | PTGS2 114/4885PTGS1 31/4885CXCL8 958/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | PTGS2 2908/4885PTGS1 2524/4885CXCL8 3230/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | PTGS2 436/4885PTGS1 263/4885CXCL8 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.